Precision Genome Engineering in Human Disease: Expanding Therapeutic Roles of CRISPR Technologies

Abstract

The advent of CRISPR-Cas9 technology has revolutionized genome editing, enabling precise modifications to the human genome with unprecedented accuracy and sequence specificity. This review examines current mechanistic insights, translational advances, and clinical developments in gene editing, focusing on applications in diabetes mellitus, cancer, hematologic disorders, neurodegenerative diseases, and autoimmune pathologies. This study provides a comprehensive analysis of recent literature on CRISPR-based genome editing, emphasizing next-generation modalities like base editing and prime editing, and their impact on target specificity and genomic integrity. Therapeutic strategies involving ex vivo editing of hematopoietic stem cells and in vivo delivery approaches, including lipid nanoparticle-mediated systems, are evaluated. Base editing and prime editing have improved sequence specificity and reduced double-strand DNA breaks, enhancing safety profiles. Ex vivo editing of hematopoietic stem cells for hemoglobinopathies and in vivo genome editing via lipid nanoparticles show translational promise. However, limitations persist: off-target effects, immunogenicity, delivery inefficiencies, and ethical concerns surrounding germline editing require careful consideration. Gene editing technologies show potential for treating previously intractable diseases. Technical, safety, and ethical challenges must be addressed through continued refinement of editing platforms, rigorous scientific validation, and the establishment of robust governance frameworks to ensure safe and responsible translation into clinical medicine.

Introduction

CRISPR-Cas9 technology has revolutionized genome editing, enabling precise modifications to the human genome with unprecedented accuracy and sequence specificity. This review examines current mechanistic insights, translational advances, and clinical developments in gene editing, with a focus on applications in diabetes mellitus, cancer, hematologic disorders, neurodegenerative diseases, and autoimmune pathologies.[1,2] The advent of CRISPR-Cas9 has catalyzed a shift toward precision medicine, with therapeutic interventions tailored to individual genetic profiles. Clinical applications include the treatment of genetic disorders, cancers, and regenerative medicine. Base editing and prime editing have improved sequence specificity and reduced double-strand DNA breaks, enhancing safety profiles. [3,4]. Ex vivo editing of hematopoietic stem cells for hemoglobinopathies and in vivo genome editing via lipid nanoparticles show translational promise [5,6]. However, limitations persist, such as off-target effects, immunogenicity, delivery inefficiencies, and ethical concerns surrounding germline editing, which require careful consideration. Ongoing research focuses on optimizing delivery and specificity to enhance therapeutic efficacy.[7].Gene editing technologies show potential for treating previously intractable diseases.[8] Technical, safety, and ethical challenges must be addressed through continued refinement of editing platforms, rigorous scientific validation, and the establishment of robust governance frameworks to ensure safe and responsible translation into clinical medicine.

Materials and Methods

This narrative review comprehensively surveyed recent advances in CRISPR-Cas9-mediated therapeutic genome editing. A structured search of PubMed, Scopus, Web of Science, and Google Scholar was conducted using keywords including "CRISPR-Cas9," "genome editing," "gene therapy," and disease-specific terms. English-language publications from the last decade were prioritized, with seminal earlier studies included as necessary. Eligibility criteria encompassed original research articles, clinical trials, and reviews addressing CRISPR-based genome editing mechanisms, applications, delivery, safety, and ethics in human health. Preclinical studies with translational relevance were included. Data extraction focused on study design, disease targets, editing platforms, delivery systems, efficiency, off-target effects, and outcomes, emphasizing landmark clinical studies. This review was not prospectively registered. Studies were evaluated for methodological rigor, reproducibility, and clinical relevance, with preference given to high-impact peer-reviewed sources. Evidence was synthesized thematically into the therapeutic applications, delivery systems, and ethical considerations of genome editing.

Figure 1:

PRISMA Flow Diagram

Molecular Mechanisms of CRISPR-Mediated Genome Editing

CRISPR-Cas9 genome editing is driven by the generation of site-specific DNA double-strand breaks, guided by a synthetic single-guide RNA to target genomic loci.[9] Target recognition requires a protospacer adjacent motif (PAM), a critical determinant of specificity.[10,11] Endogenous DNA repair pathways are activated, with outcomes dictated by the balance between non-homologous end joining (NHEJ) and

homology-directed repair (HDR).[12,13] NHEJ predominates in somatic cells, introducing insertion-deletion mutations, while HDR enables precise sequence modification with a donor template, albeit with lower efficiency and cell-cycle dependence. [14,15]. Recent advances have improved editing precision and reduced reliance on double-strand breaks.[16,17] Base editing systems allow direct nucleotide conversion without DNA cleavage, minimizing genomic instability and off-target effects. [18,19]. Prime editing enables targeted insertions, deletions, and base substitutions via reverse transcriptase [20,21]. While these technologies show promise, efficiency varies across cell types, and off-target activity persists. Ongoing studies evaluate long-term genomic stability and clinical applicability. [22-24]

Gene Editing in Hematologic Disorders: A Curative Paradigm

CRISPR-based therapeutics have advanced clinically for hereditary blood disorders like sickle cell disease and beta-thalassemia, which result from hemoglobin mutations.[25-27] A key strategy involves CRISPR-mediated disruption of the BCL11A erythroid enhancer, reactivating fetal haemoglobin expression to compensate for defective adult haemoglobin. [28,29] Ex vivo edited hematopoietic stem cells, such as ex vivo gene autotemcel, have shown promising outcomes in clinical trials, including reduced transfusion requirements and vaso-occlusive episodes.[30,31] However, these studies involve small cohorts and limited follow-up, requiring longer-term data to confirm efficacy, clonal stability, and safety. Gene editing thus represents a promising therapeutic approach, but definitive curative potential remains under evaluation.

Oncologic Applications involve reprogramming the Immune System.

Genome editing technologies have revolutionized cancer immunotherapy by enabling the engineering of T lymphocytes with enhanced antitumor activity.[32,33] CRISPR-mediated disruption of immune checkpoint molecules like PD-1 enhances T-cell cytotoxicity and partially overcomes tumor-induced immune suppression.[34,35] This approach has facilitated the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies with improved specificity and persistence.[36,37] Clinical trials have demonstrated the feasibility and safety of CRISPR-edited CAR-T cells in treating various cancers, including B-cell lymphoma and multiple myeloma. [38,39] For instance, a phase 1 clinical trial (NCT03399448) showed that CRISPR-Cas9 gene editing of T cells from patients with advanced cancer was safe and feasible, with edited T cells persisting in patients for up to 9 months.[40-42]

However, challenges persist, including variable efficacy across tumor types, potential off-target edits, and safety concerns related to cytokine release and immune-related toxicities.[43] Tumor heterogeneity also limits the effectiveness of single-target approaches. [44] CRISPR-based targeting of oncogenic drivers is under investigation, but achieving efficient and selective delivery to tumor cells in vivo remains a major obstacle.[46] Ongoing research aims to address these challenges, including the development of more precise genome editing tools and improved delivery systems. The potential of CRISPR-Cas9 technology in cancer immunotherapy is significant, with several clinical trials underway to evaluate its safety and efficacy.[47]

The Application of Gene Editing in Neurodegenerative Disorders

CRISPR-based approaches aim to silence or correct pathogenic genes in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. [48,49] Preclinical studies targeting mutant HTT in Huntington's disease have demonstrated reduced protein aggregation and improved neuronal survival.[50]. However, clinical translation is hindered by challenges, including delivery across the blood-brain barrier, cell-type specificity, and potential off-target effects in long-lived neuronal populations.[51] Engineered viral vectors and nanoparticle-based systems have improved CNS delivery, but clinical evidence remains limited, and long-term safety data are lacking.[52] Ongoing research focuses on optimizing delivery and specificity to enhance therapeutic efficacy.

The Application of Gene Editing in Autoimmune Diseases: Recalibrating Immune Tolerance

Autoimmune diseases result from dysregulated immune recognition of self-antigens, leading to chronic inflammation and tissue damage.[53] Gene editing offers a strategy to restore immune tolerance through targeted modification of immune cell populations. Approaches include enhancing regulatory T-cell suppressive function and eliminating autoreactive B-cell receptors, potentially achieving more selective immunomodulation than conventional therapies.[54,55] Preclinical studies demonstrate promise, but challenges persist in maintaining long-term tolerance, avoiding unintended immune dysregulation, and ensuring safety in complex immune environments.[56]. Clinical validation in large, controlled trials is required to establish efficacy and safety.

Application of Gene Editing in the Functional Cure of Diabetes Mellitus

Genome editing strategies for diabetes mellitus aim to restore endogenous insulin production and protect pancreatic β-cells from immune-mediated destruction.[57,58] CRISPR-based modification of donor-derived pancreatic islet cells reduces immune recognition by altering major histocompatibility complex expression, supporting sustained insulin production without systemic immunosuppression in early clinical observations. [59,60] Induced pluripotent stem cells have enabled the generation of patient-specific insulin-producing cells, with transplantation studies demonstrating restored glycemic control and reduced insulin dependence in small cohorts.[61,62] Clinical trials like VX-880 support stem cell-derived islet replacement feasibility, but scalability, cost, and durability remain unresolved. [63,64] Combined CRISPR-based immune evasion and stem cell-derived β-cell production strategies are under development. Current evidence is preliminary, with concerns regarding off-target effects, genomic stability, and autoimmune recurrence risk.[65]

Delivery Systems: A Critical Bottleneck in Clinical Translation

Efficient tissue-specific delivery of CRISPR components remains a central limitation in clinical translation. Viral vectors, particularly adeno-associated viruses, offer high transduction efficiency but are constrained by limited cargo capacity and potential. [66] Non-viral delivery systems, including lipid nanoparticles, have shown promise in hepatic applications like transthyretin amyloidosis, with early-phase clinical studies demonstrating measurable in vivo editing.[67]. Emerging platforms like extracellular vesicles and biodegradable polymers aim to improve targeting specificity and reduce immune activation.[68] Challenges persist in achieving consistent delivery efficiency across tissues, enabling repeated dosing, and minimizing off-target distribution. Integration of nanotechnology and molecular engineering has proven successful in addressing these limitations.[69]

Ethical and Biosecurity Considerations in Genome Editing

The clinical application of genome editing raises very important ethical and regulatory considerations, particularly in germline modification. Heritable genome editing presents challenges related to consent, long-term societal impact, and potential misuse for non-therapeutic enhancement.[70]. Stringent regulatory oversight and international coordination are emphasized by global health organizations, promoting responsible research practices, transparency, and risk assessment. [71]. Biosecurity concerns are significant, given the potential misuse of gene editing technologies in engineered pathogens. Addressing these risks requires robust governance structures, ongoing surveillance, and international collaboration to align technological advances with ethical and public health priorities. [72]

Conclusion

Genome editing has rapidly advanced from experimental research to early clinical application across multiple disease domains. Evidence from hematologic disorders, cancer immunotherapy, neurodegenerative disease models, autoimmune conditions, and diabetes suggests CRISPR-based approaches hold broad therapeutic potential.[73-76] However, current clinical data are largely derived from early-phase trials and limited patient populations, with substantial challenges remaining. Improving

delivery efficiency, enhancing editing specificity, and establishing long-term safety through well-designed clinical studies are key priorities. Addressing ethical and regulatory considerations is equally important for responsible implementation. Continued interdisciplinary research and carefully controlled clinical translation will determine the extent to which genome editing can be integrated into standard medical practice.

Given the current limitations, we recommend prioritizing the development of more efficient and specific delivery systems, alongside rigorous long-term safety assessments in diverse patient populations.